23 March 2018
ImmuPharma PLC
("ImmuPharma" or the "Company")
Lupuzor™ Pivotal Phase III Study Update
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announces that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III trial study, that 'database lock' is expected on 6 April 2018, with top line results announced by mid-April 2018.
Lupuzor™ is the Company's lead programme for the potential breakthrough compound for Lupus, a life threatening autoimmune disease.
Commenting on the trial update, Tim McCarthy, Chairman, said: "With the continued robust safety record of Lupuzor™ achieved over this trial, we look forward with confidence to reporting top line results in the near future."
For more information on the trial please visit: https://clinicaltrials.gov/ct2/show/NCT02504645
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
For further information please contact:
ImmuPharma plc (www.immupharma.com) |
+ 44 (0) 20 7152 4080 |
Tim McCarthy, Chairman |
|
Lisa Baderoon, Head of Investor Relations Twitter: @immupharma |
+ 44 (0) 7721 413496 |
|
|
Northland Capital Partners Limited David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance Rob Rees, Corporate Broking |
+44 (0)20 3861 6625 |
|
|
|
|
